Doctoral Dissertation Defense Announcement

“Epigenetic Regulation in Normal and Malignant Hematopoiesis”

Olivia Arnold
Candidate for Doctor of Philosophy
Cell and Developmental Biology
School of Graduate Studies
Medical College of Wisconsin

Committee in Charge:
Dr. Nan Zhu, PhD (Mentor)
Dr. Sid Rao, PhD
Dr. John Pulikkan, PhD
Dr. Demin Wang, PhD
Dr. Subramaniam Malarkannan, PhD
Dr. Panagiotis Ntziachristos, PhD

Date: Wednesday, March 13th, 2024
Time: 10:00 AM (CST)
Defense Location: VBRI Seminar Room
Zoom: contact oarnold@mcw.edu for zoom link
Graduate Studies:

Foundations in Biomedical Science I-IV
Techniques and Molecular and Cell Biology
Professional Development I-II
Writing a Scientific Paper
Writing an Individual Fellowship
Reading and Research
Advanced Cell Biology
Statistics for Basic Sciences
Developmental and Stem Cell Biology
Basic Immunology
Ethics & Integrity in Science
Research Ethics Discussion Series
Doctoral Dissertation
Hematopoietic stem cells (HSCs) govern hematopoiesis through the processes of self-renewal and differentiation. The balance between these processes must be highly regulated to avoid hematopoietic dysfunction or malignant transformation. Epigenetic regulation is essential for regulating and maintaining proper hematopoiesis, and mutations of epigenetic regulators in hematopoietic stem and progenitor cells (HSPCs) are frequent drivers of hematological malignancies. Understanding the mechanisms behind the roles of epigenetic regulators in hematopoiesis can give insights into the pathophysiology of hematological diseases.

The Switch/Sucrose Non-Fermenting (SWI/SNF) nucleosome remodeling complexes are implicated in all stages of hematopoiesis and mutations of complex subunits have been observed over 25% of all cancers. One of the dominant forms of mammalian SWI/SNF is the BRG1/BRM Associated Factor (BAF) complex. BAF is distinguished from other SWI/SNF complexes by its incorporation of ARID1 proteins, Arid1a or Arid1b. Arid1a plays a crucial role in blood development. However, the role of Arid1b in this context is not well understood.

We utilized hematopoietic specific Cre mouse models to understand the role of Arid1b in normal hematopoiesis. We discovered Arid1b is dispensable for steady state and non-competitive hematopoiesis as the frequencies of all blood cell types were unaltered after its loss. Interestingly, we found Arid1b loss impairs the regenerative potential of HSPCs as we observed decreased chimerism of donor myeloid and HSPCs in competitive transplantations. Reconstitution of B cells was also impaired in constitutive knockout models only. These defects seemed to occur with incomplete penetrance as they were only observed in some transplantations dependent upon the donor mouse. We conclude Arid1b is largely dispensable for normal hematopoiesis but is required for HSC function under competitive conditions.

Acute Myeloid Leukemia (AML) is the most common leukemia in adults resulting from buildup of immature myeloid blast cells in the bone marrow and other tissues, eventually leading to hematopoietic failure if left untreated. Standard care for AML patients includes chemotherapy, however, 30-40% of patients will relapse, highlighting a need for more effective therapeutics.

A subset of patients with AML presents with chromosomal rearrangements of the mixed lineage leukemia (MLL1) gene, which result in the development of onco-fusion proteins that drive disease. The most common rearrangement of MLL1 (MLLr) in AML is MLL-AF9. JMJD1C, a member of the lysine demethylase 3 (KDM3) protein family, is a downstream target of MLL-AF9 and is aberrantly expressed in MLLr leukemias. Loss of JMJD1C causes differentiation and cell death of murine MLL-AF9 cells in vitro and impairment of leukemogenesis in vivo. Importantly, JMJD1C is dispensable for normal hematopoiesis, highlighting its potential as a therapeutic target. The role and function of of JMJD1C in human MLL-AF9 leukemia, however, is not well understood.

We utilized a CRISPR/Cas9 ribonucleoprotein (RNP) system to knockout JMJD1C in a human CD34+ umbilical cord blood derived model of MLL-AF9 leukemia (CD34-MLL-AF9). Loss of JMJD1C led to increased myeloid differentiation and apoptosis in vitro and impaired MLL-AF9 leukemogenesis in vivo. Further, we uncovered a novel interaction between JMJD1C and the nuclear co-repressor complex (NCoR) in human MLL-AF9, AML1-ETO, and PML-RARα cells. RNAseq analysis suggested this interaction may function to promote oncogenic fatty acid (FA) metabolism, as we observed significant downregulation of key players upon knockout of either JMJD1C or NCoR1. Further, we observed enrichment of FA metabolism pathways in the commonly downregulated genes. Together, this data proves a requirement of JMJD1C in human MLL-AF9 leukemia and shows JMJD1C interacts with NCoR to mediate oncogenic metabolism promoting leukemogenesis.

By studying the roles of Arid1b and JMJD1C respectively in normal hematopoiesis and AML, our work contributes to the understanding of epigenetic regulation in normal development and disease and identifies potential a therapeutic target for AML.
Olivia Arnold
Curriculum Vitae
oarnold@mcw.edu

Education

- Medical College of Wisconsin – 2024 (expected)
  - PhD in Cell & Developmental Biology
- Marquette University- 2018
  - Bachelor of Science in Biology
  - Minor: Psychology

Professional Experience

- Graduate Student Research Assistant- Cell and Developmental Biology (2019-2024)
  - Medical College of Wisconsin and Versiti Blood Research Institute, Milwaukee, WI
- Undergraduate Intern- Molecular Immunology and Immunotherapy (2017)
  - Blood Center of Wisconsin, Milwaukee, WI

Other Experience and Professional Memberships

- Event Leadership Team- Relay for Life of Greater Milwaukee (2020-Present)
- Grassroots Member- American Cancer Society Cancer Action Network (2020-Present)
- Sub-Committee Co-Chair- Driving Equity and Inclusion for Students in Science (2023-2024)
- Co-Chair- Enhancing Scholarly Culture Committee (2023-2024)
- American Society of Hematology Leadership Institute (2023)
- Student Coach- Interdisciplinary Program in Biomedical Sciences (2020-2023)
- Chair- Young Professionals of the American Cancer Society (2020-2023)

Honors and Awards

- Education Committee Award- Versiti Blood Research Institute (2023)
- Graduate Student Travel Award- Medical College of Wisconsin (2022)
- Graduate Student Travel Award- Cell and Developmental Biology (2022)

Publications

- Abstracts

Publications


Submitted Manuscripts